PATENT CLAIM ANALYSIS

Application Number: 15747581
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "036000"]

Abstract:
A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

Claim (Index 7):
A compound according to  claim 1  or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is:\n 4\u2033-N-methylapramycin, \n 4\u2033-N-(3-aminopropyl)apramycin, \n 4\u2033-N-((1-aminocyclopentyl)methyl)apramycin, \n 4\u2033-N-(1,3-diaminopropan-2-yl)apramycin, \n 4\u2033-N,N-bis(2-aminoethyl)apramycin, \n 4\u2033-N-(cis-1,4-4-aminocyclohexyl)apramycin, \n 4\u2033-N-(trans-1,4-4-aminocyclohexyl)apramycin, \n 4\u2033-N-(azetidin-3-yl)apramycin, \n 4\u2033-N-(1-methylazetidin-3-yl)apramycin, \n 4\u2033-deamino-4\u2033-guanidinoapramycin, \n 4\u2033-N-guanidinoethylapramycin, \n 5-epiapramycin, \n 5-deoxy-5-epi-5-fluoroapramycin, \n 6-deoxy-5-epi apramycin, \n 5,6-dideoxy-5-fluoroapramycin, \n 5-amino-5-deoxy-5-epiapramycin, \n 5-amino-5-deoxyapramycin, \n 6-amino-5,6-dideoxy-5,6-diepi-5-fluoroapramycin, \n 5-amino-5,6-dideoxyapramycin, \n 2\u2033-amino-2\u2033-deoxy-2\u2033, 3\u2033-diepiapramycin, \n 3\u2033-amino-3\u2033-deoxyapramycin, \n 3\u2033-epiapramycin, \n 2\u2033, 3\u2033-diepiapramycin, \n 6\u2033-deoxy-6\u2033-fluoroapramycin, \n 3\u2033, 6\u2033-dideoxyapramycin, \n 5,6\u2033-dideoxyapramycin, \n 5,3\u2033-dideoxyapramycin, \n 3\u2033-deoxy-5-epiapramycin, \n 5,3\u2033-dideoxy-5-epi-5-fluoroapramycin, \n 6,3\u2033-dideoxy-5-epiapramycin, \n 5,6,3\u2033-trideoxyapramycin, \n 5-amino-5,3\u2033-dideoxy-5-epiapramycin, \n 5,2\u2033-dideoxy-5,3\u2033-diepi-5-fluoroapramycin, \n 5,3\u2033-diepiapramycin, \n 6,6\u2033-dideoxy-5-epiapramycin, \n 5-eno-5,6,6\u2033-trideoxyapramycin, \n 5,6,6\u2033-trideoxyapramycin, \n 5-deoxy-4\u2033-N-methylapramycin, \n 4\u2033-N-(2-aminoethyl)-5-deoxyapramycin, \n 4\u2033-N-(3-aminopropyl)-5-deoxyapramycin, \n 5-deoxy-4\u2033-N-(1,3-diaminopropan-2-yl)apramycin, \n 4\u2033-deamino-5-deoxy-4\u2033-guanidinoapramycin, \n 5-epi-4\u2033-N-methylapramycin, \n 4\u2033-N-(2-aminoethyl)-5-epiapramycin, \n 4\u2033-N-(3-aminopropyl)-5-epiapramycin, \n 4\u2033-N-(1,3-diaminopropan-2-yl)-5-epiapramycin, \n 4\u2033-deamino-5-epi-4\u2033-guanidinoapramycin, \n 4\u2033-deamino-5-deoxy-5-epi-5-fluoro-4\u2033-guanidinoapramycin, \n 5,6-dideoxy-4\u2033-N-methylapramycin, \n 4\u2033-N-(2-aminoethyl)-5,6-dideoxyapramycin, \n 4\u2033-N-(3-aminopropyl)-5,6-dideoxyapramycin, \n 4\u2033-N-(1,3-diaminopropan-2-yl)-5,6-dideoxyapramycin, \n 4\u2033-deamino-5,6-dideoxy-4\u2033-guanidinoapramycin, \n 6-deoxy-5-epi-4\u2033-N-methylapramycin, \n 4\u2033-N-(2-aminoethyl)-6-deoxy-5-epiapramycin, \n 4\u2033-N-(3-aminopropyl)-6-deoxy-5-epiapramycin, \n 4\u2033-deamino-6-deoxy-5-epi-4\u2033-guanidinoapramycin, \n 4\u2033-N-(1,3-diaminopropan-2-yl)-5,6\u2033-dideoxyapramycin, \n 4\u2033-deamino-5,6\u2033-dideoxy-4\u2033-guanidinoapramycin, \n 4\u2033-deamino-5,3\u2033-dideoxy-4\u2033-guanidinoapramycin, \n 4\u2033-N-glycylapramycin, \n 4\u2033-N-sarcosylapramycin, \n 4\u2033-N-(L-alanyl)apramycin, \n 4\u2033-N-(D-alanyl)apramycin, \n 4\u2033-N-(L-seryl)apramycin, \n 4\u2033-N-(D-seryl)apramycin, \n 4\u2033-N-(\u03b2-alanyl)apramycin, \n 4\u2033-N-(L-isoseryl)apramycin, \n 5-epi-4\u2033-N-glycylapramycin, \n 5-epi-4\u2033-N-sarcosylapramycin, \n 4\u2033-N-(L-alanyl)-5-epiapramycin, \n 5-epi-4\u2033-N-(L-seryl)apramycin, \n 4\u2033-N-(\u03b2-alanyl)-5-epiapramycin, \n 5-epi-4\u2033-N-(L-isoseryl)apramycin, \n 5-epi-4\u2033-N-(D-isoseryl)apramycin, \n 6-deoxy-5-epi-4\u2033-N-glycylapramycin, \n 6-deoxy-5-epi-4\u2033-N-sarcosylapramycin, \n 4\u2033-N-(\u03b2-alanyl)-6-deoxy-5-epiapramycin, \n 6-deoxy-5-epi-4\u2033-N-(L-isoseryl)apramycin, \n 5-amino-4\u2033-deamino-5-deoxy-5-epi-4\u2033-guanidinoapramycin, \n 5-amino-5-deoxy-5-epi-4\u2033-N-glycylapramycin, \n 5-amino-5-deoxy-5-epi-4\u2033-N-(L-isoseryl)apramycin, \n 4\u2033-deamino-3\u2033-deoxy-5-epi-4\u2033-guanidinoapramycin, \n 4\u2033-deamino-5,3\u2033-dideoxy-5-epi-5-fluoro-4\u2033-guanidinoapramycin or \n 2\u2033-deoxy-5,3\u2033-diepiapramycin.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 86.0
- Lexical Diversity: 1.62264
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10698924', '14382390', '10240725', '12226745', '11271136']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7383808996628156
- 35 USC 102 Novelty (BERT): 0.4924211208550063
- Combined Prediction Score: 0.7137849217820348
- Mean Citation Score: 223.08697
- Max Citation Score: 236.89209
- Similarity Product: 199.6404024211943

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test